Neeraj Saini
Overview
Explore the profile of Neeraj Saini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pasvolsky O, Marcoux C, Wang Z, Milton D, Pal B, Tanner M, et al.
Transplant Cell Ther
. 2025 Jan;
31(3):166.e1-166.e9.
PMID: 39746546
Patients with multiple myeloma (MM) without high-risk cytogenetic abnormalities are classified as having standard-risk MM (SRMM), and data focusing on their outcomes after autologous hematopoietic stem cell transplantation (autoHCT) are...
2.
Manzar G, Dudzinski S, Yoder A, Seo A, Nasr L, Rafei H, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Dec;
PMID: 39709251
Background: The prognosis of multiple myeloma involving the central nervous system (CNS-MM) is poor. We report outcomes of CNS-MM treated with CNS-directed radiation therapy (RT). Methods: We retrospectively reviewed patients...
3.
Marcoux C, Pasyar S, Milton D, Khan H, Tanner M, Bashir Q, et al.
Br J Haematol
. 2024 Nov;
206(2):763-765.
PMID: 39610225
No abstract available.
4.
Pasvolsky O, Marcoux C, Milton D, Pal B, Tanner M, Bashir Q, et al.
Blood Cancer J
. 2024 Nov;
14(1):189.
PMID: 39482325
Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34 cell dose remains unclear. We conducted a retrospective study on MM patients undergoing upfront...
5.
Marcoux C, Pasvolsky O, Milton D, Tanner M, Bashir Q, Srour S, et al.
Transplant Cell Ther
. 2024 Oct;
31(1):12.e1-12.e10.
PMID: 39448031
Despite tremendous advancements in multiple myeloma (MM) therapeutics, outcomes remain heterogeneous, heavily influenced by clinical and cytogenetic factors. Among these, deletion of the short arm of chromosome 17 (del(17p)) is...
6.
Pasvolsky O, Marcoux C, Dai J, Milton D, Tanner M, Syed N, et al.
Transplant Cell Ther
. 2024 Jun;
30(8):772.e1-772.e11.
PMID: 38852784
Upfront autologous stem cell transplantation (auto-SCT) remains standard of care for eligible patients with newly diagnosed multiple myeloma (NDMM), although recently its role has been questioned. The aim of the...
7.
Pasvolsky O, Wang Z, Milton D, Tanner M, Bashir Q, Srour S, et al.
Blood Cancer J
. 2024 May;
14(1):82.
PMID: 38760362
Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small proportion achieve a durable response....
8.
Alzahrani K, Pasvolsky O, Wang Z, Milton D, Tanner M, Bashir Q, et al.
Br J Haematol
. 2024 Mar;
204(5):1944-1952.
PMID: 38448009
The second revision of the International Staging System (R2-ISS) is a simple tool to risk-stratify newly diagnosed multiple myeloma (NDMM) patients. Here, we completed a retrospective analysis to evaluate the...
9.
Pasvolsky O, Ghanem S, Milton D, Rauf M, Tanner M, Bashir Q, et al.
Blood Cancer J
. 2024 Jan;
14(1):4.
PMID: 38199987
The prognostic impact of additional copies of chromosome 1q (1q + ) on outcomes of newly-diagnosed multiple myeloma (NDMM) patients undergoing autologous transplantation (autoSCT) is unclear. We conducted a retrospective...
10.
Pasvolsky O, Pasyar S, Bassett R, Khan H, Tanner M, Bashir Q, et al.
Cancer
. 2023 Dec;
130(9):1663-1672.
PMID: 38127583
Background: The prognostic significance of minimal residual disease (MRD) status before autologous hematopoietic stem cell transplantation (autoHCT) in patients with multiple myeloma (MM) has not been clearly elucidated. Methods: Retrospective...